MedTrace Logo

Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)

NCT04664075 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2024-05-17

Study results available
· View outcomes & findings →

Summary

Respiratory infections such as colds, flu and pneumonia affect millions of people around the world every year. Most cases are mild, but some people become very unwell. Influenza ('flu') is one of the most common causes of lung infection. Seasonal flu affects between 10% and 46% of the population each year and causes around 12 deaths in every 100,000 people infected. In addition, both influenza and coronaviruses have caused pandemics in recent years, leading to severe disease in many people. Although flu vaccines are available, these need to change every year to overcome rapid changes in the virus and are not completely protective.

This study aims to find and develop predictive tests to better understand how and when flu-like illness progresses to more severe disease. This may help to decide which people need to be admitted to hospital, and how their treatment needs to be increased or decreased during infection.

The aim is to recruit 100 patients admitted to hospital due to a respiratory infection. It is voluntary to take part and participants can choose to withdraw at any time. The study will involve some blood and nose samples. This will be done on Day 0, Day 2 and Discharge from hospital, and an out-patient follow-up visit on Day 28. The data will be used to develop novel diagnostic tools to assist in rational treatment decisions that will benefit both individual patients and resource allocation. It will also establish research preparedness for upcoming pandemics.

Conditions

  • Influenza
  • SARS (Severe Acute Respiratory Syndrome)
  • Respiratory Viral Infection
  • Respiratory Tract Infections
  • Infection, Bacterial
  • Infection Viral
  • Covid19
  • RNA Virus Infections

Interventions

BIOLOGICAL

Respiratory infections

With biological samples and longitudinal observations, the aim is to find and develop predictive tests to better understand how and when flu-like illness progresses to more severe disease. This may help to decide which people need to be admitted to hospital, and how their treatment needs to be increased or decreased during infection.

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Christopher Chiu, PhD · Imperial College London

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-25
Primary Completion
2022-04-30
Completion
2022-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04664075 on ClinicalTrials.gov